Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
Total Valuation
Biodexa Pharmaceuticals has a market cap or net worth of $4.14M. The enterprise value is -$2.66M.
Market Cap$4.14M
Enterprise Value-$2.66M
Share Statistics
Biodexa Pharmaceuticals has 619,523 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding619,523
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biodexa Pharmaceuticals’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -85.12%.
Return on Equity (ROE)-0.69
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-85.12%
Return on Capital Employed (ROCE)-0.94
Revenue Per Employee0.00
Profits Per Employee-440.69K
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Biodexa Pharmaceuticals is ―. Biodexa Pharmaceuticals’s PEG ratio is -0.00086.
PE Ratio―
PS Ratio0.00
PB Ratio0.24
Price to Fair Value0.24
Price to FCF-0.15
Price to Operating Cash Flow-0.02
PEG Ratio-0.00086
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 0.00 and earned -5.73M in profits. Earnings per share was -1.16M.
Revenue0.00
Gross Profit-5.44M
Operating Income-9.20M
Pretax Income-5.98M
Net Income-5.73M
EBITDA-9.08M
Earnings Per Share (EPS)-1.16M
Cash Flow
In the last 12 months, operating cash flow was -10.76M and capital expenditures -776.00K, giving a free cash flow of -11.53M billion.
Operating Cash Flow-10.76M
Free Cash Flow-11.53M
Free Cash Flow per Share-18.62
Dividends & Yields
Biodexa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-89.00%
50-Day Moving Average6.69
200-Day Moving Average19.48
Relative Strength Index (RSI)53.07
Average Volume (3m)41.98K
Important Dates
Biodexa Pharmaceuticals upcoming earnings date is Apr 24, 2026, TBA (Confirmed).
Last Earnings DateSep 12, 2025
Next Earnings DateApr 24, 2026
Ex-Dividend Date―
Financial Position
Biodexa Pharmaceuticals as a current ratio of 1.75, with Debt / Equity ratio of 8.74%
Current Ratio1.75
Quick Ratio1.75
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Biodexa Pharmaceuticals has paid -250.00K in taxes.
Income Tax-250.00K
Effective Tax Rate0.04
Enterprise Valuation
Biodexa Pharmaceuticals EV to EBITDA ratio is -22.08K, with an EV/FCF ratio of -15.38K.
EV to Sales0.00
EV to EBITDA-22.08K
EV to Free Cash Flow-15.38K
EV to Operating Cash Flow-16.35K
Balance Sheet
Biodexa Pharmaceuticals has $4.04M in cash and marketable securities with $501.00K in debt, giving a net cash position of $3.53M billion.
Cash & Marketable Securities$4.04M
Total Debt$501.00K
Net Cash$3.53M
Net Cash Per Share$5.71
Tangible Book Value Per Share$43.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Biodexa Pharmaceuticals is $18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.00
Price Target Upside172.31% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast86.75%